Skip to main content


Log in

Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

  • Reviews and New Research Implications (S. Virani, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript


Purpose of Review

This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress.

Recent Findings

Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE).


Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others



Ambulatory blood pressure


Acute coronary syndrome


Atherosclerotic cardiovascular disease


Blood pressure


Coronary artery calcium


Coronary artery disease


Chronic coronary syndrome


Coronary computed tomography angiography


Confidence interval


C-reactive protein


Cardiovascular disease


Diastolic blood pressure


Docosahexaenoic acid




Estimated glomerular filtration rate


Eicosapentaenoic acid


European Society of Cardiology


Fibrous cap thickness


Fixed-dose combination


Fractional flow reserve


Heart failure


Heart failure with preserved ejection fraction


Heart failure with reduced ejection fraction


Hospitalization for heart failure


High-intensity statin


Hyperemic myocardial blood flow


Hazard ratio


Invasive coronary angiography


Intravascular ultrasound


Low-density lipoprotein cholesterol


Major adverse cardiac events


Major coronary events


Myocardial infarction


Myocardial perfusion imaging


Magnetic resonance imaging


Non-ST-elevation MI


Optical coherence tomography


Odds ratio


Percutaneous coronary intervention


Proprotein convertase subtilisin/kexin type 9


Randomized controlled trial


Relative risk


Relative risk reduction


Systolic blood pressure


Standard deviation


Single photon emission computed tomography


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021. In a randomized trial of 5988 heart failure patients with left ventricular ejection fraction >40%, empagliflozin (compared with placebo) was associated with a significant risk reduction in the composite end point of cardiovascular death and first hospitalization for heart failure.

  2. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727–38. In a randomized trial of 4,744 heart failure patients with reduced left ventricular ejection fraction, dapagliflozin (compared with placebo) was associated with a significant risk reduction in the composite end point of ventricular arrhythmias and sudden death.

  3. Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An individual participant data meta-analysis. Lancet. 2021;398(10306):1133–46.

    Article  PubMed  CAS  Google Scholar 

  4. Doi T, Langsted A, Nordestgaard BG. A possible explanation for the contrasting results of reduce-it vs. Strength: Cohort study mimicking trial designs. Eur Heart J. 2021.

  5. Nicholls SJ, Nissen SE, Prati F, et al. Assessing the impact of pcsk9 inhibition on coronary plaque phenotype with optical coherence tomography: Rationale and design of the randomized, placebo-controlled huygens study. Cardiovasc Diagn Ther. 2021;11(1):120–9 This international double-blind, placebo-controlled randomized controlled trial of 161 patients demonstrated that adding evolucomab to statin therapy among patients after an acute coronary syndrome resulted in a greater increase in minimum fibrous cap thickness and decrease in maximum lipid arc.

    Article  Google Scholar 

  6. Jain V, Al Rifai M, Mahtta D, Liu J, Hussain A, Virani SS. Highlights from studies presented at the virtual american college of cardiology scientific sessions 2021: Staying updated with the latest advancements in prevention. Curr Atheroscler Rep. 2021;23(9):50.

    Article  Google Scholar 

  7. Hussain A, Al Rifai M, Mahtta D, Liu J, Jain V, Virani SS. Highlights from studies presented at the american heart association scientific session 2020: Navigating new roads in prevention. Curr Atheroscler Rep. 2021;23(1):4.

    Article  CAS  Google Scholar 

  8. Al Rifai M, Jia X, Al-Mallah MH, Miedema MD, Martin SS, Virani SS. Major randomized clinical trials in cardiovascular disease prevention presented at the 2019 american college of cardiology annual scientific session. Curr Atheroscler Rep. 2019;21(8):31.

    Article  Google Scholar 

  9. Jia X, Al Rifai M, Gluckman TJ, Birnbaum Y, Virani SS. Highlights from selected cardiovascular disease prevention studies presented at the 2019 european society of cardiology congress. Curr Atheroscler Rep. 2019;21(12):46.

    Article  Google Scholar 

  10. Knuuti J, Wijns W, Saraste A, et al. 2019 esc guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.

    Article  Google Scholar 

  11. Jones T, Townsend D. History and future technical innovation in positron emission tomography. J Med Imaging (Bellingham). 2017;4(1):011013.

    Article  Google Scholar 

  12. Devine CE, Mawlawi O. Radiation safety with positron emission tomography and computed tomography. Semin Ultrasound CT MR. 2010;31(1):39–45.

    Article  Google Scholar 

  13. Desiderio MC, Lundbye JB, Baker WL, Farrell MB, Jerome SD, Heller GV. Current status of patient radiation exposure of cardiac positron emission tomography and single-photon emission computed tomographic myocardial perfusion imaging. Circ Cardiovasc Imaging. 2018;11(12):e007565.

    Article  Google Scholar 

  14. Mcmurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.

    Article  CAS  Google Scholar 

  15. Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384(3):216–28 This meta-analysis of large randomized controlled trials assessed a fixed-dose combination strategy approach of at least 2 BP lowering agents and statin (with or without aspirin) versus a control (placebo or usual care) in a primary cardiovascular disease prevention patient population.

    Article  CAS  Google Scholar 

  16. Miedema MD, Huguelet J, Virani SS. Aspirin for the primary prevention of cardiovascular disease: In need of clarity. Curr Atheroscler Rep. 2016;18(1):4.

    Article  CAS  Google Scholar 

  17. Miedema MD, Virani SS. Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding. Evid Based Med. 2016;21(6):225.

    Article  Google Scholar 

  18. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 acc/aha guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e563–95.

    PubMed  PubMed Central  Google Scholar 

  19. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13.

    Article  CAS  Google Scholar 

  20. Mcneil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–18.

    Article  CAS  Google Scholar 

  21. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.

    Article  CAS  Google Scholar 

  22. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The strength randomized clinical trial. JAMA. 2020;324(22):2268–80.

    Article  CAS  Google Scholar 

  23. Virani SS, Nambi V, Ballantyne CM. Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of reduce-it and strength. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):e7-8.

    Article  Google Scholar 

  24. Chow CK, Gupta R. Blood pressure control: A challenge to global health systems. Lancet. 2019;394(10199):613–5.

    Article  Google Scholar 

  25. Chow CK, Thakkar J, Bennett A, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: Placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017;389(10073):1035–42.

    Article  CAS  Google Scholar 

  26. Prati F, Romagnoli E, Gatto L, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: The clima study. Eur Heart J. 2020;41(3):383–91.

    PubMed  Google Scholar 

  27. Kataoka Y, Puri R, Hammadah M, et al. Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. Am J Cardiol. 2014;114(4):549–54.

    Article  CAS  Google Scholar 

  28. Zou Z, Cini K, Dong B, et al. Time trends in cardiovascular disease mortality across the brics: An age-period-cohort analysis of key nations with emerging economies using the global burden of disease study 2017. Circulation. 2020;141(10):790–9.

    Article  Google Scholar 

  29. Huo Y. Current status and development of percutaneous coronary intervention in china. J Zhejiang Univ Sci B. 2010;11(8):631–3.

    Article  Google Scholar 

  30. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.

    Article  CAS  Google Scholar 

  31. Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to p2y12 inhibition, in acute coronary syndromes (gemini-acs-1): A double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799–808.

    Article  CAS  Google Scholar 

Download references


This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16–072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), the American Diabetes Association Clinical Science and Epidemiology award (1–14- CE-44), and the Houston VA Health Services Research & Development Center for Innovations grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs or the US government. The Department of Veterans Affairs or the US government had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Salim S. Virani.

Ethics declarations

Conflict of Interest

Michelle T. Lee, Dhruv Mahtta, Mahmoud Al Rifai, Louis Dlouhy, Hunaina Shahab: None.

Salim S. Virani: Honorarium, American College of Cardiology (Associate Editor for Innovations,

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Reviews and New Research Implications

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, M.T., Mahtta, D., Dlouhy, L. et al. Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress. Curr Atheroscler Rep 23, 76 (2021).

Download citation

  • Accepted:

  • Published:

  • DOI: